alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 476–500 of 1,127 studies · tagged Digital Tools (page 20 of 46) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Predictive factors for dementia among older adults in South Korea: an interpretable machine learning analysis

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s Research & Therapy 2025-11-13

Predictive performance was comparable across algorithms, with R² ranging from 0.201 to 0.361, highest in the MCI_All dataset. 5 key findings →

Design: longitudinal study Participants: 4,958 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Classification of AD and bvFTD using neuropsychological and neuropsychiatric variables: a machine learning study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-10-01

Among 1616 participants (AD = 1498, bvFTD = 118), all algorithms achieved high accuracy (80% to 90%) and discriminatory ability (AUC = 0.89 to 0.95). 5 key findings →

Participants: 1,616 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Resource-stratified machine learning framework for cognitive status classification and mild cognitive impairment to dementia progression prediction

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s Research & Therapy 2026-03-07

The Level 3 model achieved high classification performance (AUC: 93.98%), and the Level 1 model achieved comparable performance (AUC: 91.53%). 5 key findings →

Participants: 31,081 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer’s Disease: A Targeted Mass Spectrometry and Machine Learning Approach

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neuropsychiatric Disease and Treatment 2026-03-01

Significant alterations were observed in 7 lipid classes and 65 specific lipid species in DLB compared to AD. 5 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development of a neural network-based risk prediction model for mild cognitive impairment in older adults with functional disability

✓ Peer-reviewed alzhub usefulness score 46 out of 100. BMC Public Health 2025-06-02

The results indicated that residence location, alcohol consumption, life satisfaction, depressive symptoms, and education level are key factors influencing the risk of MCI among older adults with functional disability. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The effects of an immersive virtual reality and telemedicine-based multi-component intervention in individuals with subjective cognitive decline: study protocol of a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Psychology 2025-07-11

Our results will provide new evidence of the efficacy of an innovative multi-component intervention integrating IVR and telemedicine in SCD individuals. 2 key findings →

Participants: 75 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-02

Models including plasma biomarkers yielded the most accurate predictions of tau-PET burden (best model: R-squared = 0.66-0.69), with especially high contribution from plasma phosphorylated tau-217 (p-tau217). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Blood biomarker-based classification study for neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Scientific reports 2023-10-11

As the population ages, neurodegenerative diseases are becoming more prevalent, making it crucial to comprehend the underlying disease mechanisms and identify biomarkers to allow for early diagnosis and effective screening for clinical trials. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Color Fundus Photography and Deep Learning Applications in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Mayo Clinic proceedings. Digital health 2024-08-26

The self-supervised ADRET model had superior accuracy when compared with ADVAS, in both UK Biobank (98.27% vs 77.20%; P<.001) and our institutional testing data sets (98.90% vs 94.17%; P=.04). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Using Technology to Facilitate Fidelity Assessments: The Tele-STAR Caregiver Intervention

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of medical Internet research 2019-05-24

Tele-STAR reduced caregiver burden and retained good program and treatment fidelity to STAR-C. We found Tele-STAR reduced caregiver burden and had good fidelity to the original protocol. 4 key findings →

Participants: 13 Evidence: low

Full summary, score breakdown and related studies → Original source

Telemedicine and the evaluation of cognitive impairment: the additive value of neuropsychological assessment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the American Medical Directors Association 2014-06-07

Teleneuropsychology is proving to be an excellent resource for clarifying cognitive and psychiatric diagnoses, and integrating individual strengths, weaknesses, and preferences into treatment and care plans used by other health care providers, patients, and caregivers. 5 key findings →

Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Video-telemedicine in a memory disorders clinic: evaluation and management of rural elders with cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2011-10-24

VTM is emerging as an effective way to provide consultation and care to rural residents who may not have access to specialty services and can be integrated into current clinical settings. 3 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Mobile Technology for Cognitive Assessment of Older Adults: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Innovation in aging 2019-01-01

Twenty-nine articles met our inclusion criteria and were categorized into 3 groups as follows: (a) mobile versions of existing article or computerized neuropsychological tests; (b) new cognitive tests developed specifically for mobile platforms; and (c) the use of new types of data for cognitive assessment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Application of advanced machine learning methods on resting-state fMRI network for identification of mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain imaging and behavior 2016-09-01

The study of brain networks by resting-state functional magnetic resonance imaging (rs-fMRI) is a promising method for identifying patients with dementia from healthy controls (HC). 2 key findings →

Participants: 89 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of a Digital Literacy Program on Older Adults' Digital Social Behavior: A Quasi-Experimental Study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International journal of environmental research and public health 2022-09-29

In South Korea, digital literacy education programs are expected to help its older population participate in online welfare services to increase their social support, self-esteem and well-being. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in neuroscience 2021-03-31

Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Biomarkers for the Early Detection of Mild Cognitive Impairment: Artificial Intelligence Meets Virtual Reality

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in human neuroscience 2020-07-24

Elderly people affected by Mild Cognitive Impairment (MCI) usually report a perceived decline in cognitive functions that deeply impacts their quality of life. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of cognitive impairment via deep learning trained with multi-center neuropsychological test data

✓ Peer-reviewed alzhub usefulness score 45 out of 100. BMC medical informatics and decision making 2019-11-21

The machine learning algorithm for NPTs has suggested potential use as a reference in differentiating cognitive impairment in the clinical setting. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 1,120 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed